SNOA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sonoma Pharmaceuticals Inc (SNOA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The lack of strong trading signals, neutral insider and hedge fund sentiment, and weak financial performance trends suggest that this stock does not present a compelling long-term investment opportunity at this time.
The MACD is slightly positive but contracting, RSI is neutral at 43.252, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels indicate limited upside potential in the short term, with the stock trading near its pivot level of 2.336.
Revenue increased by 22.03% YoY in the latest quarter, and gross margin improved to 37.94%, up 6.48% YoY.
Net income dropped by -11.75% YoY, EPS declined by -23.81% YoY, and there is no recent news or significant trading trends from insiders or hedge funds. Additionally, no recent congress trading data is available.
In Q3 2026, revenue grew by 22.03% YoY to $4,349,000, but net income fell to -$819,000 (-11.75% YoY), and EPS dropped to -0.48 (-23.81% YoY). Gross margin improved to 37.94% (+6.48% YoY).
No analyst rating or price target data is available for SNOA.
